Neural tube defects (NTDs) are congenital malformations of the brain and spinal cord caused by failure of the neural tube to close between 21 and 28 days following conception. Each year almost 400.000 infants are born with NTDs all over the world. Although many advances have been made in the spina bifida’s treatment and have led to an increased life expectancy and an improved life quality, no treatment exists that will completely eliminate the serious disability or premature mortality associated with it. For such a reason, reducing the risk of NTDs is an important goal. It is widely ac-cepted that adequate maternal consumption of folic acid before pregnancy and during the early weeks of gestation can reduce the danger of having a child with a neural tube defect (NTD). As a result, public health authorities worldwide have recommended consuming 400 μg folic acid per day during the periconceptional period in order to decrease the risk of first occurrence NTDs . This recommended dose is based mainly on the amount of folic acid associated with a reduction in NTDs in the majority of epidemiological studies. Literature data asserts that folic acid can prevent about 70% of NTD conceptions while folic acid-containing multivitamin can prevent about 90%; the diagnostic efficacy of ultrasound is nearly 100% in anencephalic fetuses and about 80% in fetuses with different manifestations of spina bifida. A bibliographical research regarding folate and NTD prevention, between 1988 and 2012, was done. The words used for Literature research were: Folic Acid, Spina bifida, Neural Tube Defects, Malformations. Search engines employed were: Medline, Pubmed, PopLine and the most relevant reports on the topic.
| Published in | Science Journal of Clinical Medicine (Volume 2, Issue 2) |
| DOI | 10.11648/j.sjcm.20130202.13 |
| Page(s) | 47-51 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2013. Published by Science Publishing Group |
Folic Acid, Spina bifida, Neural Tube Defects, Malformations
| [1] | Blencowe H., Cousens S., Modell B., Lawn J. "Folic acid to reduce neonatal mortality from neural tube disorders" – In-ternational Journal of Epidemiology 2010; 39: i110-i121. |
| [2] | S.Sciarretta , V.Leanza FUNDAMENTAL OBSTETRIC AND GYNECOLOGIC ELEMENTS (Test Book) Edizione S.p.e. Catania.ISBN 978-88-96808-05-4 2011 |
| [3] | V. Leanza OSTETRICIA- EDIZIONI MINERVA MEDICA EDITOR S.P.A. 2009. (Test Book) ( ISBN 10: 88-7711-631-5) ( ISBN 13: 978-88-7711-631-4). |
| [4] | McIntosh N, Helms PJ, Smyth RL (eds). Forfar & Arneil’s. Textbook of Pediatrics. 6th edn. Churchill Livingstone: Edinburgh, 2003, pp. 902–907. |
| [5] | Wyszynski DF (ed). Neural Tube Defects: from Origin to Treatment. US: Oxford University Press, 2006. |
| [6] | Yi Y., Lindemann M., Colligs A., Snowball C. "Economic burden of neural tube defects and impact of prevention with folic acid: a literature review" – Eur J Pediatr (2011) 170: 1391-1400. |
| [7] | Department of Health Scottish Office Home and Health De-partment, Welsh Office, Department of Health and Social Services, Northern Ireland. Report from an Expert Advisory Group on Folic Acid and the Prevention of Neural Tube De-fects; Department of Health: London, UK, 1992. |
| [8] | Public Health Service, Centers for Disease Control and Pre-vention. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb. Mortal. Wkly. Rep. 1992, 41, 1–7. |
| [9] | National Health and Medical Research Council. Revised Statement on the Relationship between Dietary Folic Acid and Neural Tube Defects Such As Spina Bifida; NHMRC: Melbourne, Australia, 1993. |
| [10] | Commission of the European Communities. Nutrient and Energy Intakes for the European Community; Reports of the Scientific Committee for Food Thirty-First Series; Office for Official Publications of the European Communities: Luxembourg, 1993. |
| [11] | Mulinare, J.; Cordero, J.F.; Erickson, J.D.; Berry, R.J. Peri-conceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988, 260, 3141–3145. |
| [12] | Milunsky, A.; Jick, H.; Jick, S.S.; Bruell, C.L.; MacLaughlin, D.S.; Rothman, K.J.; Willett, W. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. JAMA 1989, 262, 2847–2852. |
| [13] | Werler, M.M.; Shapiro, S.; Mitchell, A.A. Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993, 269, 1257–1261. |
| [14] | Shaw, G.M.; Schaffer, D.; Velie, E.M.; Morland, K.; Harris, J.A. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. Epidemiology 1995, 6, 219–226. |
| [15] | Khoury, M.J.; Shaw, G.M.; Moore, C.A.; Lammer, E.J.; Mu-linare, J. Does periconceptional multivitamin use reduce the risk of neural tube defects associated with other birth defects? Data from two population-based case-control studies. Am. J. Med. Genet. 1996, 61, 30–36. |
| [16] | Czeizel A., Dudàs I, paput L., Banhidy F. "Prevention of Neural-Tube defects with periconceptional folic acid, me-thylfolate, or multivitamins?" – Ann Nutr Metab 2011; 58: 263-271. |
| [17] | Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine me-tabolism in pregnancies complicated by neural-tube defects. Lancet. 1995; 345: 149-151. |
| [18] | Busby A, Abramsky L, Dolk H et al: Preventing neural tube defects in Europe: a missed opportunity. Reprod Toxicol 2005; 20: 393–402 |
| [19] | CDC: Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube de-fects. MMWR 1992; 41: 1233–1238. |
| [20] | Prinz-Langenohl R, Brämswig S, Tobolski O, Smulders YM, Smith DE, Finglas PM, Pietrzik K: [6S]-5-methyltetrahydrofolate increases plasma folate more effec-tively than folic acid in women with homozygous or wild-type 677C-T polymorphism of methylenetetrahydrofolate reductase. Br J Pharmacol 2009; 158: 2014–2021. |
| [21] | Wright AJ, King MJ, Finglas PM: Folate-supplemented oral contraceptives: does 6S-5- methytetrahydrofolic acid (Meta-folin) offer advantages over folic acid? Gynaecol Forum 2010; 15: 29–32. |
| [22] | Pietrzik K, Bailey L, Shane B: Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacoki-netics and pharmacodynamics. Clin Pharmacokinet 2010; 49: 535–548. |
| [23] | Pietrzik K, Lamers Y, Brämswig S, Prinz- Langenohl R: Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women in childbearing age. Am J Clin Nutr 2007; 86: 1414–1419. |
| [24] | Holzgreve W: Adding folate to the pill to prevent neural tube defects. Gynaecol Forum 2010; 15: 4–8. |
| [25] | Oakley D, Sereika S, Bogue EL: Oral contraceptive pill use after an initial visit to a family planning clinic. Fam Plann Perspect 1991; 23: 151–154. |
| [26] | Carbonaro A, Leanza V, Iozza I, Stracquadanio M, Formuso C, Ciotta L: screening for preeclampsia and iugr by doppler echo-flowmetry of the uterine district in the first trimester of pregnancy. International Journal of Gynecology and Obste-trics Volume 119, Supplement 3 (2012), Page S739. |
| [27] | Johnson CY, Honein MA, Dana Flanders W, Howards PP, Oakley GP Jr, Rasmussen SA.Pregnancy termination fol-lowing prenatal diagnosis of anencephaly or spina bifida: A systematic review of the literature. Birth Defects Res A Clin Mol Teratol. 2012 Nov; 94(11): 857-63. doi: 10.1002/ bdra.23086. Epub 2012 Oct 25. |
APA Style
Leanza V., Stracquadanio M., Ciotta L., Pafumi C., Giannone T. T., et al. (2013). Folates and Prevention of Neural-Tube Diseases. Science Journal of Clinical Medicine, 2(2), 47-51. https://doi.org/10.11648/j.sjcm.20130202.13
ACS Style
Leanza V.; Stracquadanio M.; Ciotta L.; Pafumi C.; Giannone T. T., et al. Folates and Prevention of Neural-Tube Diseases. Sci. J. Clin. Med. 2013, 2(2), 47-51. doi: 10.11648/j.sjcm.20130202.13
AMA Style
Leanza V., Stracquadanio M., Ciotta L., Pafumi C., Giannone T. T., et al. Folates and Prevention of Neural-Tube Diseases. Sci J Clin Med. 2013;2(2):47-51. doi: 10.11648/j.sjcm.20130202.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjcm.20130202.13,
author = {Leanza V. and Stracquadanio M. and Ciotta L. and Pafumi C. and Giannone T. T. and Giunta M. R. and Leanza G. and Mayada Chammas and Fawzi Chammas and Zarbo G.},
title = {Folates and Prevention of Neural-Tube Diseases},
journal = {Science Journal of Clinical Medicine},
volume = {2},
number = {2},
pages = {47-51},
doi = {10.11648/j.sjcm.20130202.13},
url = {https://doi.org/10.11648/j.sjcm.20130202.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjcm.20130202.13},
abstract = {Neural tube defects (NTDs) are congenital malformations of the brain and spinal cord caused by failure of the neural tube to close between 21 and 28 days following conception. Each year almost 400.000 infants are born with NTDs all over the world. Although many advances have been made in the spina bifida’s treatment and have led to an increased life expectancy and an improved life quality, no treatment exists that will completely eliminate the serious disability or premature mortality associated with it. For such a reason, reducing the risk of NTDs is an important goal. It is widely ac-cepted that adequate maternal consumption of folic acid before pregnancy and during the early weeks of gestation can reduce the danger of having a child with a neural tube defect (NTD). As a result, public health authorities worldwide have recommended consuming 400 μg folic acid per day during the periconceptional period in order to decrease the risk of first occurrence NTDs . This recommended dose is based mainly on the amount of folic acid associated with a reduction in NTDs in the majority of epidemiological studies. Literature data asserts that folic acid can prevent about 70% of NTD conceptions while folic acid-containing multivitamin can prevent about 90%; the diagnostic efficacy of ultrasound is nearly 100% in anencephalic fetuses and about 80% in fetuses with different manifestations of spina bifida. A bibliographical research regarding folate and NTD prevention, between 1988 and 2012, was done. The words used for Literature research were: Folic Acid, Spina bifida, Neural Tube Defects, Malformations. Search engines employed were: Medline, Pubmed, PopLine and the most relevant reports on the topic.},
year = {2013}
}
TY - JOUR T1 - Folates and Prevention of Neural-Tube Diseases AU - Leanza V. AU - Stracquadanio M. AU - Ciotta L. AU - Pafumi C. AU - Giannone T. T. AU - Giunta M. R. AU - Leanza G. AU - Mayada Chammas AU - Fawzi Chammas AU - Zarbo G. Y1 - 2013/03/10 PY - 2013 N1 - https://doi.org/10.11648/j.sjcm.20130202.13 DO - 10.11648/j.sjcm.20130202.13 T2 - Science Journal of Clinical Medicine JF - Science Journal of Clinical Medicine JO - Science Journal of Clinical Medicine SP - 47 EP - 51 PB - Science Publishing Group SN - 2327-2732 UR - https://doi.org/10.11648/j.sjcm.20130202.13 AB - Neural tube defects (NTDs) are congenital malformations of the brain and spinal cord caused by failure of the neural tube to close between 21 and 28 days following conception. Each year almost 400.000 infants are born with NTDs all over the world. Although many advances have been made in the spina bifida’s treatment and have led to an increased life expectancy and an improved life quality, no treatment exists that will completely eliminate the serious disability or premature mortality associated with it. For such a reason, reducing the risk of NTDs is an important goal. It is widely ac-cepted that adequate maternal consumption of folic acid before pregnancy and during the early weeks of gestation can reduce the danger of having a child with a neural tube defect (NTD). As a result, public health authorities worldwide have recommended consuming 400 μg folic acid per day during the periconceptional period in order to decrease the risk of first occurrence NTDs . This recommended dose is based mainly on the amount of folic acid associated with a reduction in NTDs in the majority of epidemiological studies. Literature data asserts that folic acid can prevent about 70% of NTD conceptions while folic acid-containing multivitamin can prevent about 90%; the diagnostic efficacy of ultrasound is nearly 100% in anencephalic fetuses and about 80% in fetuses with different manifestations of spina bifida. A bibliographical research regarding folate and NTD prevention, between 1988 and 2012, was done. The words used for Literature research were: Folic Acid, Spina bifida, Neural Tube Defects, Malformations. Search engines employed were: Medline, Pubmed, PopLine and the most relevant reports on the topic. VL - 2 IS - 2 ER -
Email: